Cancer Vaccines: Milestones, Promises, Opportunities, and Challenges (Online CE Course)

(based on 57 customer ratings)

Author: Dr. Nancy Liu-Sullivan, PhD; Reviewers: Julie Ann West, PhD, MLS(ASCP)CM, SM(ASCP)CM; Kanan Patel MBA, MT(ASCP)

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 178 CE courses, most popular
$109Add to cart
Pick Your Courses
Up to 8 CE hours
$55Add to cart
Individual course$25Add to cart
Need multiple seats for your university or lab? Get a quote

This course covers milestones, promises, opportunities, and challenges of cancer vaccines in the world today, describing both preventive and therapeutic cancer vaccines in detail. Technology, current research, and development are covered.

See all available courses

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 1 hour(s)
Approved through 4/30/2026
Florida Board of Clinical Laboratory Personnel Credit Hours - General (Serology/Immunology): 1 hour(s)
Approved through 4/30/2026

Objectives

  • Describe the leading types of cancer vaccines.
  • Explain the mechanism of action of cancer vaccines.
  • Distinguish preventive from therapeutic cancer vaccines.
  • Explain the importance of cancer neoantigen(s) in designing personalized mRNA vaccines.
  • Discuss an awareness of the challenges of cancer vaccine efficacy.

Customer Ratings

(based on 57 customer ratings)

Course Outline

Click on the links below to preview selected pages from this course.
  • TOPIC 1: VACCINE OVERVIEW
      • Vaccine Overview
      • Vaccine Overview: Summary by Vaccine Types
      • Vaccine Overview: Summary by Vaccine Types, continued
      • True or False? Live attenuated vaccines contain weakened forms of disease-causing germs.
      • True or False? Adenovirus vector-based vaccines are dangerous because there is a chance for people who have received the vaccine to suffer from adenov...
      • The mRNA vaccines are useful as:
  • TOPIC 2: CANCER MOLECULAR TRICKS TO ESCAPE IMMUNE SURVEILLANCE
      • Cancer Molecular Tricks To Escape Immune Surveillance
      • True or False? Classical Class I HLA is responsible for facilitating effective antigen presentation to activate Killer T cells.
      • True or False? Non-Classical Class I HLA are crucial for enabling NK cells to recognize cells that must be eliminated.
      • Cancer cells use three major molecular schemes to minimize the chance for them to be recognized by host immune cells. All of the following are potenti...
  • TOPIC 3: PREVENTIVE CANCER VACCINES: HPV VACCINES
      • Preventive Cancer Vaccines: HPV Vaccines
      • Preventive Cancer Vaccines: HPV Vaccines - Mechanism of action
      • Preventive Cancer Vaccines: HPV Vaccines - Efficacy
      • True or False? All three types of HPV vaccines cover HPV 16 and HPV 18.
      • True or False? Vaccine cross-protection phenomenon refers to immune protection going beyond molecular targets targeted by the vaccine.
      • All of the following statements about HPV vaccine mechanisms of action are true, except:
  • TOPIC 4: PREVENTIVE CANCER VACCINES (continued): HBV VACCINES
      • Preventive Cancer Vaccines (continued): HBV Vaccines
      • True or False? The first generation of hepatitis B vaccine based on carrier-derived blood plasma product was replaced by a non-blood product out of co...
      • True or False? Aluminum hydroxide Al(OH)3 was incorporated into the second-generation non-blood-based hepatitis B vaccine with the intent of making th...
      • What is TWINRIX?
  • TOPIC 5. THERAPEUTIC CANCER VACCINES: A TALE OF THREE VACCINES
      • Therapeutic Cancer Vaccines: A Tale of Three Vaccines
      • Therapeutic Cancer Vaccines: Vaccine Against Prostate Cancer
      • Therapeutic Cancer Vaccines: Vaccine Against Bladder Cancer
      • Therapeutic Cancer Vaccines: Vaccine Against Melanoma
      • True or False? Sipeucel-T vaccine introduces prostatic acid phosphate (PAP) to patient-derived dendritic cells.
      • True or False? BCG is used to treat late-stage bladder cancer.
      • True or False? T-VEC is a therapeutic vaccine that treats late-stage melanoma.
      • In addition to cancer preventive vaccines, there are also FDA-approved therapeutic cancer vaccines for cancer treatment. These include vaccines agains...
  • TOPIC 6: THE BASICS OF MESSENGER RNA TECHNOLOGY
      • The Basics of Messenger RNA Technology
      • True or False? The mRNA delivery challenge was solved with the innovative lipid nanoparticle (LNP) technology to protect mRNA from destruction by RNAs...
      • True or False? Pseudouridine protects mRNA from nuclease destruction in addition to minimizing immunogenicity by the host immune system to remove and ...
      • The idea of using mRNA to express desired proteins to solve medical issues has been around for decades. The process was met with three major challenge...
  • TOPIC 7: mRNA CANCER VACCINES: A DEVELOPING STORY
      • mRNA Cancer Vaccines: A Developing Story
      • True or False? The mRNA cancer vaccine instructs dendritic cells (DC) to make cancer-specific neoantigens to train cytotoxic T cells (CTL) for the rec...
      • True or False? The MSKCC-BioNTech pancreatic cancer vaccine successfully delayed tumor relapse by 18 months, based on data collected 18 months post-va...
      • The success of mRNA-based COVID-19 vaccines has significantly boosted confidence in the design and building of mRNA-based therapeutic cancer vaccines....
  • TOPIC 8. CANCER VACCINE RESEARCH AND DEVELOPMENT: CHALLENGES AND OPPORTUNITIES
      • Cancer Vaccine Research and Development: Challenges and Opportunities
      • True or False? Malignant tumor cells are the only cells found in a tumor.
      • True or False? Cancer stem cells make cancer cells more aggressive in proliferation and metastasis.
      • The most challenging aspect of cancer vaccine development is the identification of cancer-specific neoantigens. Which of the following statements is t...
  • References
      • References

Additional Information

Level of Instruction: Intermediate 
Intended Audience: Medical laboratory scientists, medical laboratory technicians, pathology residents, MLS students, and other health care personnel who have an interest in this subject matter.
Author Information: Dr. Nancy Liu-Sullivan served as a Senior Research Scientist with a specialty in cancer genomics and drug discovery prior to joining the biology faculty at the College of Staten Island (CSI), City University of New York (CUNY), teaching Immunology, Radiation Biology, and General Biology, in addition to mentoring students in cancer research. Dr. Liu-Sullivan is also the author of MediaLab’s CE courses titled "Hallmarks and Signaling of Cancer Cell" and "HLA and Cancer Immunotherapy".
Reviewer Information
Dr. Julie Ann West is certified by the American Society for Clinical Pathology (ASCP) as a Medical Laboratory Scientist (MLS) and as a Specialist in Microbiology (SM). In addition, Dr. West has earned a PhD in Public Health - Epidemiology Specialization (emphasis on infectious disease) - and is Certified in Public Health (CPH) by the National Board of Public Health Examiners. Dr. West is experienced as a Technical Specialist in Microbiology and Molecular specialties, Safety Officer, Educator, and Lead in the Veterans Administration Healthcare System, and has prior experience as an Administrative Laboratory Director.
Kanan Patel oversees operations at the cell therapies manufacturing facility in Hackensack University Medical Center, NJ, serving as its manager. She holds a Bachelor’s degree and an MBA from Rutgers University, with a background spanning over 25 years in clinical and pathology laboratory operations and compliance. With nearly 4 years dedicated to the field of cellular therapies, her current role emphasizes managing cellular processing operations and educational opportunities for students.
Course Description: This course covers milestones, promises, opportunities, and challenges of cancer vaccines in the world today, describing both preventive and therapeutic cancer vaccines in detail. Technology, current research, and development are covered.

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 178 CE courses, most popular
$109Add to cart
Pick Your Courses
Up to 8 CE hours
$55Add to cart
Individual course$25Add to cart
Need multiple seats for your university or lab? Get a quote
Sipuleucel-T (abbreviated process)